<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03048448</url>
  </required_header>
  <id_info>
    <org_study_id>CQAW039A2108</org_study_id>
    <nct_id>NCT03048448</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Fevipiprant (QAW039) in Patients With Hepatic Impairment Compared to Matched Healthy Subjects</brief_title>
  <official_title>An Open-label, Single-dose, Parallel-group Study to Assess the Pharmacokinetics of Fevipiprant (QAW039) in Patients With Hepatic Impairment Compared to Matched Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will characterize the pharmacokinetics (PK) of QAW039 after a single oral dose of&#xD;
      QAW039 in patients with hepatic impairment compared to healthy matched control subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine if the pharmacokinetic profile of Fevipiprant is&#xD;
      different in patients with hepatic impairment compared to healthy matched volunteers to an&#xD;
      extent that would require an adjustment of the dosage. Data from this study will be used to&#xD;
      guide enrollment criteria in future clinical trials and to support regulatory submission and&#xD;
      labeling information.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 31, 2017</start_date>
  <completion_date type="Actual">April 22, 2019</completion_date>
  <primary_completion_date type="Actual">April 22, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics: Plasma concentration of Fevipiprant by AUClast</measure>
    <time_frame>120 hours post-dose</time_frame>
    <description>AUClast is the area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Plasma concentration of Fevipiprant by AUCinf</measure>
    <time_frame>120 hours post-dose</time_frame>
    <description>AUCinf is the area under the plasma concentration-time curve from time zero to infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Plasma concentration of Fevipiprant by Cmax</measure>
    <time_frame>120 hours post-dose</time_frame>
    <description>Cmax is the observed maximum plasma concentration following drug administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relationship between plasma pharmacokinetics of Fevipiprant by AUClast and baseline hepatic function.</measure>
    <time_frame>120 hours post-dose</time_frame>
    <description>AUClast (the area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration ) related to Child Pugh score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between plasma pharmacokinetics of Fevipiprant by AUCinf and baseline hepatic function.</measure>
    <time_frame>120 hours post-dose</time_frame>
    <description>AUCinf (the area under the plasma concentration-time curve from time zero to infinity) related to Child Pugh score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between plasma pharmacokinetics of Fevipiprant by Cmax and baseline hepatic function.</measure>
    <time_frame>120 hours post-dose</time_frame>
    <description>Cmax is the observed maximum plasma concentration following drug administration related to Child Pugh score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of the metabolite CCN362 by AUClast</measure>
    <time_frame>120 hours post-dose</time_frame>
    <description>AUClast is the area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of the metabolite CCN362 by AUCinf</measure>
    <time_frame>120 hours post-dose</time_frame>
    <description>AUCinf is the area under the plasma concentration-time curve from time zero to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of the metabolite CCN362 by Cmax</measure>
    <time_frame>120 hours post-dose</time_frame>
    <description>Cmax is the observed maximum plasma concentration following drug administration</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>Fevipiprant 450mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>450mg Film Coated Tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fevipiprant</intervention_name>
    <description>Single 450mg dose</description>
    <arm_group_label>Fevipiprant 450mg</arm_group_label>
    <other_name>QAW039</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All subjects&#xD;
&#xD;
        - Weight of at least 50 kg and no more than 120 kg and have a body mass index in the range&#xD;
        18.0-36.0 kg/m2&#xD;
&#xD;
        Patients with hepatic impairment&#xD;
&#xD;
          -  Moderate hepatic impairment (Group 1): Child-Pugh Class B (7-9 points),&#xD;
&#xD;
          -  Severe hepatic impairment (Group 2): Child-Pugh Class C (10-15 points&#xD;
&#xD;
          -  Mild hepatic impairment (Group 4): Child-Pugh Class A (5-6 points)&#xD;
&#xD;
        Healthy subjects&#xD;
&#xD;
          -  Match in age (±5 years), gender, smoking status, and weight (± 15%) to an individual&#xD;
             patient.&#xD;
&#xD;
          -  In good health as determined by past medical history, physical examination,&#xD;
             electrocardiogram, laboratory tests and urinalysis at screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        All subjects&#xD;
&#xD;
          -  History of hypersensitivity and/or idiosyncracies to QAW039 or to drugs of similar&#xD;
             classes (CRTh2 antagonists).&#xD;
&#xD;
          -  Use of co-medications that may impact QAW039 exposure such as broad range UGT&#xD;
             inhibitors or strong inhibitors of OAT3, OATP1B3, and P-gp, including but not limited&#xD;
             to probenecid, ritonavir, valproic acid, and rifampin&#xD;
&#xD;
          -  Surgical or medical condition which might significantly alter the absorption,&#xD;
             distribution, metabolism, or excretion of drugs, or which may jeopardize the subject&#xD;
             in case of participation in the study.&#xD;
&#xD;
          -  History of malignancy of any organ system (other than localized basal cell carcinoma&#xD;
             of the skin), treated or untreated, within the past 5 years, regardless of whether&#xD;
             there is evidence of local recurrence or metastases.&#xD;
&#xD;
          -  Pregnant or nursing (lactating) women.&#xD;
&#xD;
          -  Women of child-bearing potential&#xD;
&#xD;
        Patients with hepatic impairment&#xD;
&#xD;
          -  Hepatic impairment due to non-liver disease (e.g., right heart failure)&#xD;
&#xD;
          -  Current symptoms or history of encephalopathy Grade III or IV within the past 6 months&#xD;
&#xD;
          -  Primary biliary liver cirrhosis and biliary obstruction&#xD;
&#xD;
          -  Emergency room visit or hospitalization due to liver disease within the preceding 3&#xD;
             months.&#xD;
&#xD;
          -  Severe complications of liver disease within the preceding 3 months.&#xD;
&#xD;
        Healthy subjects&#xD;
&#xD;
          -  Liver disease or liver injury as indicated by abnormal liver function tests.&#xD;
&#xD;
          -  Any single parameter of ALT, AST, γ-GT, alkaline phosphatase or serum bilirubin must&#xD;
             not exceed 1.5 x upper limit of normal (ULN)&#xD;
&#xD;
          -  Any elevation above ULN of more than one parameter of ALT, AST, γ GT, alkaline&#xD;
             phosphatase or serum bilirubin will exclude a subject from participation in the study&#xD;
&#xD;
          -  A positive Hepatitis B surface antigen or Hepatitis C test result.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Romania</country>
  </removed_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17633</url>
    <description>Results for CQAW039A2108 from the Novartis Clinical Trials Website</description>
  </link>
  <link>
    <url>https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=516</url>
    <description>A Plain Language Trial Summary is available on novartisclinicatrials.com</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 27, 2017</study_first_submitted>
  <study_first_submitted_qc>February 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2017</study_first_posted>
  <last_update_submitted>December 9, 2020</last_update_submitted>
  <last_update_submitted_qc>December 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatic impairment,</keyword>
  <keyword>Fevipiprant,</keyword>
  <keyword>adults,</keyword>
  <keyword>pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

